EDINA, Minn.--(Business Wire)--
LecTec Corporation (OTCBB:LECT) announced today that it has
engaged the law firm of Rader, Fishman & Grauer PLLC to represent it
in connection with its patent portfolio. Rader, Fishman & Grauer ranks
as one of the top patent litigation firms in the US and has
represented clients in more than three hundred federal court cases
since 1996. Rader Fishman is recognized as a "go to" law firm by
companies engaged in patent litigation. LecTec will be working with R.
Terrance Rader, considered one of the country's top patent litigators
with over three decades of experience, along with Thomas E. Bejin and
Glenn Forbis who each have in excess of fifteen years of patent trial
experience. LecTec looks forward to working with the Rader Fishman
firm.
About LecTec Corporation
LecTec Corporation is an intellectual property licensing and
holding company. The Company's primary focus is to derive royalty and
other income from patents that the Company owns based on its advanced
skin interface technologies. The Company was an innovator in
hydrogel-based topical delivery of therapeutic over-the-counter
medications, which provide alternatives to topical creams and
ointments. A hydrogel is a gel-like material having an affinity for
water and similar compounds. These gels are ideal for delivering
medication onto the skin. The Company holds multiple domestic and
international patents on its hydrogel technology.
Cautionary Statements
This press release contains forward-looking statements concerning
possible or anticipated future results of operations or business
developments which are typically preceded by the words "believes,"
"wants," "expects," "anticipates," "intends," "will," "may," "should,"
or similar expressions. Such forward-looking statements are subject to
risks and uncertainties, which could cause results or developments to
differ materially from those, indicated in the forward-looking
statements. Such risks and uncertainties include, but are not limited
to, the Company's dependence on royalty payments from Novartis
Consumer Health, Inc. ("Novartis"), which recently began selling an
adult vapor patch licensed by the Company, the Company's dependence on
key personnel and Board of Director members, the success or failure of
any attempt by the Company to protect or enforce its patents and
territories of coverage, the issuance of new accounting
pronouncements, the availability of opportunities for licensing
agreements related to patents that the Company holds, limitations on
market expansion opportunities, and other risks and uncertainties
detailed from time to time in the Company's filings with the
Securities and Exchange Commission, and particularly as described in
the "Cautionary Statements" filed as Exhibit 99.01 to our Form 10-KSB
for the year ended December 31, 2007.
LecTec Corporation
Bill Johnson, Controller, 952-933-2291 X24
Copyright Business Wire 2008
